Inhibitory effects of SARS-CoV-2 nonstructural proteins on the RIG-I signaling pathway
1.85 MB
avoin
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty.
Lataukset231
Pysyvä osoite
Verkkojulkaisu
DOI
Tiivistelmä
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from the Coronaviridae family is an enveloped, spherical virus with a 30 kb long non-segmented positive single-stranded RNA genome, which encodes for 16 non-structural, four structural, and eleven accessory proteins. It was first discovered in 2019 in Wuhan, Hubei province, China, from a patient suffering from pneumonia caused by a previously unknown virus. SARS-CoV-2 rapidly spread throughout Wuhan, after which it spread around the world, leading to the current pandemic. The common symptoms caused by SARS-CoV-2 are fever, cough, dyspnea, and myalgia, similar to other human-infecting coronaviruses such as SARS-CoV and MERS-CoV, but less severe. SARS-CoV-2 has been shown to inhibit the RIG-I pathway, disrupting the production of type I and III interferons, and to evade host innate immune response.
In this study, I analyzed whether some SARS-CoV-2 proteins have an ability to inhibit the production of type III interferon by interfering with the RIG-I pathway. Additionally, I checked if the ORF9B accessory protein was immunogenic. To accomplish this, I cloned the genes of interest into mammalian expression vectors, which were then transfected to HEK-293 cells along with a constitutively active form of RIG-I and IFN-1 promoter luciferase reporter plasmid. Structural proteins were incapable of inhibiting RIG-I induced activation of type III interferon promoter, while nonstructural proteins Nsp1, Nsp6, and Nsp13 showed clear inhibitory activity. ORF9B was found not to be immunogenic.